The Society for Immunotherapy of Cancer (SITC) hosted this comprehensive cancer immunotherapy program, in Mesa, Ariz., Feb. 18–22, 2019. Taught by leading experts, this five-day program provided attendees a deep understanding of the core principles of tumor immunology and cancer immunotherapy and examined developing areas in the field.
Tailored to early career scientists and clinicians in the field, the program covered the fundamentals of cancer immunotherapy and allowed participants to tailor their experience by selecting the track most relevant to their educational goals.
Over the course of the week, attendees learned about:
- Core principles of tumor immunology and cancer immunotherapy
- Biomarker technology, validation and clinical integration
- Clinical trial design, data analysis and considerations for combination therapies
- Grant writing to obtain research funding
In addition to deepening their understanding, attendees benefitted from professional development while interacting with faculty and thought leaders in this intimate setting.
Target audience
- Graduate students, postdoctoral fellows and clinical fellows in the field of cancer immunotherapy
- Individuals new to the field working in academic, clinical, industry and government settings
The SITC Cancer Immunotherapy Winter School was supported in part by grants from Abbvie, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Merck & Co., Inc and Prometheus Laboratories Inc.